Alnylam Pharma (ALNY) Tops Q1 EPS by 92c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $286.59 +0.06%
Revenue Growth %: +70.6%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +70.6%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($0.01), $0.92 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $594.19 million versus the consensus estimate of $588.75 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley upgrades CDW on stronger AI-driven server demand
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
- Increasing unusual option volume: BLZE ADTN XYL BZFD DOMO IAG ARQQ PRIM USAS IVV ALLT RPD
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
